These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 14577717)

  • 1. Defining and characterizing the late-stage biopharmaceutical pipeline.
    Nagle PC; Lugo TF; Nicita CA
    Am J Manag Care; 2003 Oct; 9(6 Suppl):S124-35. PubMed ID: 14577717
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characteristics of and trends in the late-stage biopharmaceutical pipeline.
    Nagle PC; Nicita CA; Gerdes LA; Schmeichel CJ
    Am J Manag Care; 2008 Apr; 14(4):226-9. PubMed ID: 18402515
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biopharmaceuticals: recent approvals and likely directions.
    Walsh G
    Trends Biotechnol; 2005 Nov; 23(11):553-8. PubMed ID: 16051388
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Approval of new biopharmaceuticals 1999-2006: comparison of the US, EU and Japan situations.
    Tsuji K; Tsutani K
    Eur J Pharm Biopharm; 2008 Mar; 68(3):496-502. PubMed ID: 17884403
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Managing the expanded use of biologics across therapeutic areas: an example from b-cell targeted therapies.
    Cohen M; Morrow T; Penna P
    Am J Manag Care; 2006 Mar; 12(2 Suppl):S24-37; quiz S38. PubMed ID: 16551202
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biopharmaceuticals in China.
    Hu X; Ma Q; Zhang S
    Biotechnol J; 2006 Nov; 1(11):1215-24. PubMed ID: 17089435
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nonclinical aspects of biopharmaceutical development: discussion of case studies at a PhRMA-FDA workshop.
    Buckley LA; Benson K; Davis-Bruno K; Dempster M; Finch GL; Harlow P; Haggerty HG; Hart T; Kinter L; Leighton JK; McNulty J; Roskos L; Saber H; Stauber A; Tabrizi M
    Int J Toxicol; 2008; 27(4):303-12. PubMed ID: 18821393
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differences in product information of biopharmaceuticals in the EU and the USA: implications for product development.
    Nieminen O; Kurki P; Nordström K
    Eur J Pharm Biopharm; 2005 Aug; 60(3):319-26. PubMed ID: 15996576
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aqueous two-phase systems: A viable platform in the manufacturing of biopharmaceuticals.
    Rosa PA; Ferreira IF; Azevedo AM; Aires-Barros MR
    J Chromatogr A; 2010 Apr; 1217(16):2296-305. PubMed ID: 19962707
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lessons learned from independent central review.
    Ford R; Schwartz L; Dancey J; Dodd LE; Eisenhauer EA; Gwyther S; Rubinstein L; Sargent D; Shankar L; Therasse P; Verweij J
    Eur J Cancer; 2009 Jan; 45(2):268-74. PubMed ID: 19101138
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regulating biopharmaceuticals under CDER versus CBER: an insider's perspective.
    Schwieterman WD
    Drug Discov Today; 2006 Oct; 11(19-20):945-51. PubMed ID: 16997146
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Formulations strategies for biopharmaceuticals--ensuring success to market.
    Atkinson EM; Klum W
    IDrugs; 2001 May; 4(5):557-60. PubMed ID: 16012901
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Health economics of market access for biopharmaceuticals and biosimilars.
    Simoens S
    J Med Econ; 2009 Sep; 12(3):211-8. PubMed ID: 19723019
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New biopharmaceuticals in the USA: trends in development and marketing approvals 1995-1999.
    Reichert JM
    Trends Biotechnol; 2000 Sep; 18(9):364-9. PubMed ID: 10942959
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Criteria supporting the study of drugs in the newborn.
    Ward RM; Benitz WE; Benjamin DK; Blackmon L; Giacoia GP; Hudak M; Lasky T; Rodriguez W; Selen A
    Clin Ther; 2006 Sep; 28(9):1385-98. PubMed ID: 17062311
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alternative strategies for toxicity testing of species-specific biopharmaceuticals.
    Bussiere JL; Martin P; Horner M; Couch J; Flaherty M; Andrews L; Beyer J; Horvath C
    Int J Toxicol; 2009; 28(3):230-53. PubMed ID: 19546261
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification and development of new biopharmaceuticals.
    Werner RG
    Arzneimittelforschung; 1998 May; 48(5):523-30. PubMed ID: 9638321
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The immunogenicity of biopharmaceuticals. Lessons learned and consequences for protein drug development.
    Patten PA; Schellekens H
    Dev Biol (Basel); 2003; 112():81-97. PubMed ID: 12762507
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plants as bioreactors for biopharmaceuticals: regulatory considerations.
    Miele L
    Trends Biotechnol; 1997 Feb; 15(2):45-50. PubMed ID: 9081298
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.